Page last updated: 2024-10-31

midodrine and Denys-Drash Syndrome

midodrine has been researched along with Denys-Drash Syndrome in 1 studies

Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.

Denys-Drash Syndrome: A disorder of sex development characterized by UROGENITAL ABNORMALITIES; GONADAL DYSGENESIS; and WILMS TUMOR. It is caused by a mutation in the Wilms tumor suppressor gene (GENES, WILMS TUMOR) on chromosome 11.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hassinger, AB1
Garimella, S1

Other Studies

1 other study available for midodrine and Denys-Drash Syndrome

ArticleYear
Refractory hypotension after bilateral nephrectomies in a Denys-Drash patient with phenylketonuria.
    Pediatric nephrology (Berlin, Germany), 2013, Volume: 28, Issue:2

    Topics: Adrenergic alpha-1 Receptor Agonists; Denys-Drash Syndrome; Female; Humans; Hypotension; Infant; Inf

2013